Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, September 17, 2018
Isotopen Technologien München (ITM) has signed a Research Evaluation and Option Agreement for a worldwide exclusive license with Merck KGaA, Darmstadt, Germany.
read more
Thursday, February 01, 2024
Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, has proudly announced the acquisition of a wholesale license granted by the New Jersey Department of Health (NJDOH), allowing the company to function as a virtual ...
read more
ITM Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, and Radiopharm Theranostics , a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, announced the signing of a supply agreement that ...
read more
Iterative Scopes, a provider of precision medicine technologies for gastroenterology, has acquired Clinical Research Strategy Group, LLC and Precision Research (CRSG/Precision),
read more
Friday, December 20, 2013
Many Israeli pharmaceutical executives recently learned that the 505(b)(2) development process is an important tool that can significantly reduce costs and shorten the timeline for approval of new drugs, adding substantially to ROI.
read more
Thursday, December 11, 2014
Camargo Pharmaceutical Services, a leading drug development organization specializing in the 505(b)(2) approval pathway, joined inPack to present a seminar, “Non-Clinical and Clinical Study Design Factors in a Clinical Trial Protocol,” on Dec. 9 in ...
read more
Tuesday, November 23, 2021
iSpecimen Inc., an online marketplace for human biospecimens, today announced that it has been contracted to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes, and testing validity among multiple ...
read more
ISPE, the International Society for Pharmaceutical Engineering, announced today it is currently conducting a global survey on patient experiences with clinical trial materials. The survey is designed to obtain feedback on areas such as the ...
read more
At the 3rd annual ISPE-FDA CGMP Conference, ISPE announced the official launch of its Metrics Pilot Program. The launch of the pilot, headed by ISPE’s PQLI® Quality Metrics Team, is a major milestone in the overall project from ISPE. The pilot is now...
read more
Wednesday, April 25, 2012
ISPE announced today the Food and Drug Administration (FDA) will co-sponsor the upcoming “Redefining the ‘C’ in ‘CGMP’” Conference in Baltimore, Md. USA on 4 – 5 June 2012. The conference is the first joint ISPE-FDA conference focused on CGMP issues.
read more
ISPE, the International Society for Pharmaceutical Engineering, announced today that it will work with stakeholders world-wide to produce a Drug Shortages Prevention Plan to guide the pharmaceutical and biopharmaceutical industry in establishing ...
read more
Tuesday, November 24, 2020
Isohelix announced its GeneFiX Saliva RNA Collection Device is the technology of choice for COVID-19 testing by Precision Genetics.
read more
Isogenica announced a new licensing deal with Takeda, a global research and development-driven pharmaceutical company focused on oncology, gastroenterology and central nervous system disorders.
read more
In the pharmaceutical industry, the traceability of prescription drugs is increasingly vital to the integrity of these products.
read more
Isarna Therapeutics GmbH announced today that it
has signed a strategic manufacturing agreement with Sanofi under which Sanofi will
manufacture clinical- and commercial-grade antisense oligonucleotide (ASO) compounds for
Isarna, enabling Isarna to...
read more